VAC-MAC: Vaccination and infection rates in multiple sclerosis (MS), chronic inflammatory rheumatic diseases (CIRD) or chronic inflammatory bowel diseases (CED)

VAC-MAC: Vaccination and infection rates in multiple sclerosis (MS), chronic inflammatory rheumatic diseases (CIRD) or chronic inflammatory bowel diseases (CED) - VAC-MAC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031559

Enrollment

Registered

2023-08-28

Start date

2023-02-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccine-preventable infections (influenza, pneumococcus, meningococcus, hepatitis B, varicella, TBE, diphtheria, herpes zoster) G35 M05 M06 M45 M46.8 M32.1 M32.8 M32.9 K50 K51

Interventions

Group 1: Retrospective analysis of claims data of a German statutory health insurance. Patients with the following autoimmune diseases: Multiple Sclerosis (MS), Chronic Inflammatory Rheumatic Disease

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: At least one of the following diseases: multiple sclerosis (MS), various inflammatory rheumatic diseases (CIRD) as well as chronic inflammatory bowel diseases (CED) OR (Physicians who treat these patient groups (neurology, gastroenterology, rheumatology and general medicine))

Exclusion criteria

Exclusion criteria: Younger than 18 years None of the above diseases

Design outcomes

Primary

Measure	Time frame
The overall research goal is the evidence-led development of recommendations for action to increase the vaccination rate in patients with autoimmune diseases. This is split into four operational objectives (OZ), with OZ 1 and OZ 2 examined in the first arm and OZ 3 addressed in the second arm. All results will be included in OZ 4: OZ 1: Analysis of vaccination uptake, vaccination effectiveness, occurrence of severe vaccination reactions as well as total costs from an SHI perspective in MAC patients and a matched comparison group. OZ 2: Identification of influencing factors and predictors for the uptake of relevant vaccinations among MAC patients on the basis of SHI routine data. OZ 3: Identification of barriers and facilitators to vaccination among both treating physicians and MAC patients, description of the individual vaccination strategy of treating physicians and analysis of the reasons for low vaccination rates as part of a qualitative primary data collection. OZ 4: Development of target group-oriented information materials.	—

Measure

Time frame

The overall research goal is the evidence-led development of recommendations for action to increase the vaccination rate in patients with autoimmune diseases. This is split into four operational objectives (OZ), with OZ 1 and OZ 2 examined in the first arm and OZ 3 addressed in the second arm. All results will be included in OZ 4: OZ 1: Analysis of vaccination uptake, vaccination effectiveness, occurrence of severe vaccination reactions as well as total costs from an SHI perspective in MAC patients and a matched comparison group. OZ 2: Identification of influencing factors and predictors for the uptake of relevant vaccinations among MAC patients on the basis of SHI routine data. OZ 3: Identification of barriers and facilitators to vaccination among both treating physicians and MAC patients, description of the individual vaccination strategy of treating physicians and analysis of the reasons for low vaccination rates as part of a qualitative primary data collection. OZ 4: Development of target group-oriented information materials.

—

Secondary

Measure	Time frame
The following additional endpoints will be investigated in the context of OZ 1: - Uptake of different vaccinations - Incidence of different vaccine-preventable infections (vaccine effectiveness) - Occurrence of various vaccination reactions - Health economics: Types of costs of care for vaccine-preventable infections. Medium- and long-term costs of the care of vaccine-preventable infections (days of sick leave, care, remedies and aids).	—

Measure

Time frame

The following additional endpoints will be investigated in the context of OZ 1: - Uptake of different vaccinations - Incidence of different vaccine-preventable infections (vaccine effectiveness) - Occurrence of various vaccination reactions - Health economics: Types of costs of care for vaccine-preventable infections. Medium- and long-term costs of the care of vaccine-preventable infections (days of sick leave, care, remedies and aids).

—

Countries

Germany

Contacts

Public ContactKerstin Hellwig

Klinik für Neurologie, St. Josef-Hospital Ruhr-Universität Bochum

Kerstin.Hellwig@ruhr-uni-bochum.de+49 2343224956

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026